Novation Biosciences

Novation Biosciences is a biotechnology company pioneering the discovery of small molecule therapeutics that modulate protein expression by targeting messenger RNA (mRNA). Utilizing its proprietary Quest platform, the company identifies compounds that interact with the untranslated regions (UTRs) of mRNA to either stabilize or destabilize the transcript, thereby increasing or decreasing the production of specific proteins. This innovative approach allows Novation to address "undruggable" targets that are difficult to reach with traditional protein-binding inhibitors or biologics. The company's research is primarily focused on high-impact therapeutic areas, including oncology, chronic inflammatory conditions, and rare genetic disorders. Headquartered in Vancouver, Novation Biosciences continues to advance its platform through internal development and strategic industry collaborations.